Neumora Therapeutics, Inc.

Ladies and gentlemen, thank you for standing by. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the call over to Helen Rubenstein, Vice President of Investor Relations and Corporate Strategy at Numora. Please go ahead.

Good afternoon, and thank you for joining Numora Therapeutics' fourth quarter and full year 2025 Financial Results Conference Call. Before we begin, I encourage everyone to visit the Investors and Media section of our website at numoratx.com, where you can find the press release related to today's call. With me on the call today are Chief Executive Officer Paul Burns, President Josh Pinto, Chief Operating and Development Officer Bill Arora, Chief Scientific Officer Nick Brandon, and Chief Financial Officer Mike Milligan. I'd like to point out that we will be making forward-looking statements during today's call which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional detail. With that, I'll now turn the call over to Paul.

Thanks, Helen. Good morning, everyone, and thank you for joining us. 2025 marked a year of important clinical progress and execution for Pneumora. We made meaningful strides in advancing our diverse pipeline of novel mechanism therapies, reported compelling data for NMRA 511, our oral highly potent brain penetrant and selective vasopressin 1A receptor antagonist, progressed our phase three program for Novacropran with optimizations based on key learnings from prior studies, expanded our M4PAM franchise with two new programs in clinical development and prioritized obesity as the lead indication for our brain penetrant NLRP3 inhibitor, NMRA215, and reported class-leading DIO data, all while continuing to strengthen our financial foundation. Our mission at Nemours remains clear. to advance the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients living with brain diseases. We believe through our differentiated approach, centered on advancing programs with best-in-class pharmacology and brain-penetrate chemistry, targeting novel mechanisms of action, we have the potential to deliver transformative therapies to millions of patients in need of better options. Now, as we move into 2026, Nemora is well positioned to achieve multiple potentially value-creating milestones within the next 12 months. As we approach these near-term catalysts, I'm confident in the strength of our science, the focus of our strategy, and the dedication of our distinguished Nemora team to deliver revolutionized therapies for patients living with brain diseases. I will now turn the call over to Josh to review our pipeline updates. Josh?